Aspire Biopharma Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-28.7	-12.54	4.46	3.34
Depreciation & Amortization	2.91	0.89	0.01	-
Stock-Based Compensation	21.2	-	-	-
Other Adjustments	0.61	8.56	-5.81	-4.32
Changes in Accounts Payable	-0.28	0.88	-0.03	0.13
Changes in Accrued Expenses	0.27	-	-	-
Changes in Other Operating Activities	-1.87	0.16	0.72	-0.56
Operating Cash Flow	-12.01	-2.05	-0.65	-1.41
Purchases of Investments	-	-	-	-294.69
Proceeds from Sale of Investments	-	13.78	284.92	-
Investing Cash Flow	-	13.78	284.92	-294.69
Long-Term Debt Issued	11.83	2.05	0.16	-
Long-Term Debt Repaid	-0.31	-	-	-0.25
Net Long-Term Debt Issued (Repaid)	11.51	2.05	0.16	-0.25
Issuance of Common Stock	0.4	-	-	297.15
Repurchase of Common Stock	-	-13.78	-284.92	-
Net Common Stock Issued (Repurchased)	0.4	-13.78	-284.92	297.15
Other Financing Activities	-	-	-	-0.3
Financing Cash Flow	7.49	-11.73	-284.76	296.59
Net Cash Flow	1.94	-	-0.5	0.5
Free Cash Flow	-4	-2.05	-0.65	-1.41
Free Cash Flow Per Share	-0.01	-0.00	-0.00	-36.70
Levered Free Cash Flow	11.42	0.89	-0.49	-1.66
Unlevered Free Cash Flow	-0.09	-1.16	-0.64	-1.41

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q